Theravance Biopharma Inc - Company Profile
Powered by 
All the data and insights you need on Theravance Biopharma Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Theravance Biopharma Inc Strategy Report
- Understand Theravance Biopharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Theravance Biopharma Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP3672965B1 | Grant | PYRIMIDINVERBINDUNG ALS JAK-KINASE-INHIBITOREN | A61K31/506; A61K45/06; A61K9/0014; A61K9/06; A61P17/00; A61P17/14; A61P29/00; A61P37/06; C07B2200/13; C07D403/12; C07D451/04; C07D451/14 | September 07, 2022 |
| US20220274957A1 | Application | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | C07D401/14; C07D405/14; C07D409/14; C07D413/14; C07D417/14; G01N33/5058 | September 01, 2022 |
| WO2022178215A1 | Application | AMINO AMIDE TETRAHYDRO IMIDAZO PYRIDINES AS JAK INHIBITORS | A61P11/00; C07D471/04 | August 25, 2022 |
| US11420965B2 | Grant | Pyrimidine compound as JAK kinase inhibitor | A61K31/506; A61K45/06; A61K9/0014; A61K9/06; A61P17/00; A61P17/14; A61P37/06; C07B2200/13; C07D403/12; C07D451/04; C07D451/14 | August 23, 2022 |
| JP2022120147A | Application | ＪＡＫ阻害剤化合物を使用する処置方法 | A61K31/4545; A61K9/0019; A61K9/0048; A61K9/0075; A61K9/0078; A61K9/008; A61P11/00; A61P27/02 | August 17, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer